SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
American Journal of Alzheimer's Disease and Other Dementias®
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Molinuevo, J. L.
Right arrow Articles by Villar, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Molinuevo, J. L.
Right arrow Articles by Villar, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Memantine: An antiglutamatergic option for dementia

Jose L. Molinuevo, MD, PhD

Unitat Memoria-Alzheimer, Institut Clinic Malalties del Sistema Nervios (ICMSN), Hospital Clinic i Universitari, Barcelona, Spain

Vicente Garcia-Gil, MD, PhD

Unitat Memoria-Alzheimer, ICMSN, Hospital Clinic i Universitari, Barcelona, Spain

Amparo Villar, MD

Unitat Memoria-Alzheimer, ICMSN, Hospital Clinic i Universitari, Barcelona, Spain

Alzheimer i disease (AD) is the most common form of dementia in occidental countries. Currently approved treatments for AD provide mainly symptomatic benefits without clear evidence of neuroprotection. N-methyl-D-aspartate (NADA) receptor antagonists have therapeutic potential in several central nervous system disorders, including neuroprotective treatment in chronic neurodegenerative diseases, and symptomatic treatment in other neurologic diseases. Memantine, an NMDA antagonist, has been recently approvedfor the treatment of advanced AD. Due to its mechanism of action, memantine is considered a neuroprotective drug, whose utility has been demonstrated in preclinical studies. In addition, memantine is a useful symptomatic treatmentfor AD and vascular dementia. This paper reviews both aspects of memantine as well as some basic mechanisms mediating cognition and glutamatergic neurodegeneration.

Key Words: memantine • Alzheimer's disease • dementia • NMDA • neuroprotective treatment

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 19, No. 1, 10-18 (2004)
DOI: 10.1177/153331750401900103
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 AM J ALZHEIMERS DIS OTHER DEMENHome page
C. F. Lippa
An Individualized Approach to Treatment for Alzheimer's Disease, Pick's Disease, and Other Dementias.
American Journal of Alzheimer's Disease and Other Dementias, October 1, 2006; 21(5): 354 - 359.
[Abstract] [PDF]


Advertisement